Medication Monitor

Generic Name (Trade Name—Company)
June 23, 2017

Potassium phosphate, succinylcholine chloride

(No trade names—Advanced Pharma)
Potential lack of sterility assurance prompts recall of products

Advanced Pharma (d/b/a Avella of Houston) is conducting a limited, voluntary recall in response to Hospira’s June 15, 2017, recall announcement that microbial growth was detected during a routine simulation of the manufacturing process. The products being recalled were repackaged and/or compounded at Advanced Pharma's Houston, TX, facility using certain Hospira products.

The recalled products are specific lots of potassium phosphate and succinylcholine chloride. This is a secondary recall based on  Hospira's recent recall.

Per Hospira, if the affected product is administered to a patient, the patient may experience adverse events ranging from fever, chills, and malaise to severe adverse events, including systemic invasive mycoses or systemic bacterial sepsis. The possibility of a breach in sterility assurance in distributed product, while remote, cannot be eliminated.

These products were not distributed directly to patients or consumers but to health care facilities (e.g., hospitals).

Avella and Advanced Pharma are notifying customers of the voluntary recall by phone, e-mail, and overnight mail. Customers in Arizona, California, Colorado, Delaware, Georgia, Louisiana, Nebraska, New Jersey, North Carolina, Ohio, Pennsylvania, South Carolina, Tennessee, Texas, Utah, and Washington that have any of the recalled products should immediately discontinue use and return the unused portion to Avella Specialty Pharmacy.

Customers with any of the affected medications can also reference Advanced Pharma’s website for more information on the specific lot numbers affected, product images, forms, and contact information: